Sensitivity (95% CI)
|
1st trimester
|
57.0% (47.1–66.5)
|
38.3% (29.1–48.2)
|
< 10−3
|
3rd trimester
|
64.9% (47.5–79.8)
|
54.1% (36.9–70.5)
|
0.05
|
Delivery (peripheral blood)
|
83.3% (58.6–96.4)
|
61.1% (35.7–82.7)
|
0.05
|
Delivery (placental blood)
|
40.0% (12.2 –73.8)
|
40.0% (12.2–73.8)
|
–
|
Primi and Secundigravidae
|
56.5% (41.1–71.1)
|
43.5% (28.9–58.9)
|
0.01
|
Multigravidae (3 +)
|
63.6% (54.2–72.2)
|
44.9% (35.7–54.3)
|
< 10−3
|
Asymptomatic
|
60.8% (52.3–68.9)
|
43.4% (35.1–51.9)
|
< 10−3
|
Symptomatic*
|
66.7% (41.0 –86.7)
|
50.0% (26.0–74.0)
|
0.08
|
Specificity (95% CI)
|
1st trimester
|
91.5% (86.9–94.9)
|
95.7% (92.1 –98.0)
|
0.003
|
3rd trimester
|
95.7% (92.0–98.0)
|
97.1% (93.8–99.0)
|
0.08
|
Delivery (peripheral blood)
|
96.4% (92.2–98.7)
|
97.6%(94.0–99.3)
|
0.16
|
Delivery (placental blood)
|
91.3% (86.3–94.9)
|
92.4% (87.6–95.8)
|
0.41
|
Primi and Secundigravidae
|
93.9% (88.4–97.3)
|
97.0% (92.4–99.2)
|
0.05
|
Multigravidae (3 +)
|
94.5% (92.1–96.3)
|
96.3% (94.3–97.8)
|
0.007
|
Asymptomatic
|
94.6% (92.3–96.4)
|
97.1% (95.3–98.4)
|
< 10−3
|
Symptomaticb
|
92.2% (82.7–97.4)
|
93.7% (84.8–98.3)
|
0.32
|